Primary Site >> Liver Cancer
Gene >> ZHX2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Activated oncogenes in B6C3F1 mouse liver tumors: implications for risk assessment. PMID: 3629242 |
Ref: Tumorigenicity of simian virus 40-hepatocyte cell lines: effect of in vitro and in vivo passage on expression of liver-specific genes and oncogenes. PMID: 2460744 Ref: Transforming genes in duck hepatic carcinoma--mht(raf) and Ha-ras. PMID: 2855457 Ref: Transforming activity of DNA from rat liver tumors induced by the carcinogen methyl(acetoxymethyl)nitrosamine. PMID: 2855600 |
Ref: Poly(A+)RNA levels of growth-, differentiation- and transformation-associated genes in the progressive development of hepatocellular carcinoma in the rat. PMID: 2468594 Ref: Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines. PMID: 2670201 |
Ref: Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene. PMID: 2196119 |
Ref: Proto-oncogene expression in three human hepatoma cell lines, HCC-M, HCC-T and PLC/PRF/5. PMID: 1661347 Ref: Activation of protooncogenes in spontaneously occurring non-liver tumors from C57BL/6 x C3H F1 mice. PMID: 1997158 |
Ref: Expression of oncogenes and tumor suppressor genes in human hepatocellular carcinoma and hepatoblastoma cell lines. PMID: 1335479 Ref: Pathology of spontaneous and oncogene transformed rat liver epithelial cells and derived tumours in nude mice. PMID: 1576082 |
Ref: Alterations in the methylation status and expression of the raf oncogene in phenobarbital-induced and spontaneous B6C3F1 mouse liver tumors. PMID: 7908202 |
Ref: Hypomethylation of DNA: a possible epigenetic mechanism involved in tumor promotion. PMID: 8532739 |
Ref: Comparison of effect of tumor promoter treatments on DNA methylation status and gene expression in B6C3F1 and C57BL/6 mouse liver and in B6C3F1 mouse liver tumors. PMID: 9049185 |
Ref: Roles of Akt/PKB and IKK complex in constitutive induction of NF-kappaB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice. PMID: 11431731 Ref: Mechanism of up-regulated gap junctional intercellular communication during chemoprevention and chemotherapy of cancer. PMID: 11506816 |
Ref: Hepatitis C virus and its roles in cell proliferation. PMID: 12109666 Ref: Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. PMID: 12359742 |
Ref: RNA interference may be more potent than antisense RNA in human cancer cell lines. PMID: 12542461 Ref: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. PMID: 12692057 |
Ref: Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. PMID: 15163433 Ref: Methylation profile of the promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma. PMID: 15526362 |
Ref: B-raf and Ha-ras mutations in chemically induced mouse liver tumors. PMID: 15592514 Ref: Repression of 5-aminolevulinate synthase gene by the potent tumor promoter, TPA, involves multiple signal transduction pathways. PMID: 15797241 Ref: Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines. PMID: 16054712 Ref: Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. PMID: 16474853 |
Ref: Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma. PMID: 16707376 Ref: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. PMID: 16757355 Ref: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. PMID: 16890795 Ref: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. PMID: 17178882 |
Ref: Expression of zinc-fingers and homeoboxes 2 in hepatocellular carcinogenesis: a tissue microarray and clinicopathological analysis. PMID: 17447851 Ref: Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. PMID: 17470685 Ref: Global gene expression in Ha-ras and B-raf mutated mouse liver tumors. PMID: 17514646 Ref: Changes in the antioxidant defense and hepatic drug metabolizing enzyme and isoenzyme levels, 8-hydroxydeoxyguanosine formation and expressions of c-raf.1 and insulin-like growth factor II genes during the stages of development of hepatocellular carcinoma PMID: 17554210 Ref: The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. PMID: 17668883 Ref: Molecular pathways and related target therapies in liver carcinoma. PMID: 18045179 Ref: From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. PMID: 18087180 Ref: Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. PMID: 19089671 |
Ref: Differential selection for B-raf and Ha-ras mutated liver tumors in mice with high and low susceptibility to hepatocarcinogenesis. PMID: 17928010 Ref: Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. PMID: 18026728 Ref: Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. PMID: 18176955 Ref: ZHX2 is a repressor of alpha-fetoprotein expression in human hepatoma cell lines. PMID: 18194454 Ref: Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model. PMID: 18297306 Ref: Sorafenib, a systemic therapy for hepatocellular carcinoma. PMID: 18376365 Ref: Sorafenib in advanced hepatocellular carcinoma. PMID: 18650514 Ref: Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. PMID: 18695262 Ref: Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. PMID: 18808443 Ref: [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro]. PMID: 18819900 Ref: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. PMID: 18852116 Ref: Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. PMID: 18854656 Ref: Systemic therapy of hepatocellular carcinoma: are we making progress? PMID: 18972075 |
Ref: Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib. PMID: 18506760 Ref: Management of advanced hepatocellular carcinoma in the era of targeted therapy. PMID: 19120940 Ref: Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. PMID: 19220580 Ref: Sorafenib: a review of its use in advanced hepatocellular carcinoma. PMID: 19228077 Ref: ZHX2 and ZHX3 repress cancer markers in normal hepatocytes. PMID: 19273305 Ref: Tax1 enhances cancer cell proliferation via Ras-Raf-MEK-ERK signaling pathway. PMID: 19472191 Ref: Comparative transcriptome and proteome analysis of Ha-ras and B-raf mutated mouse liver tumors. PMID: 19476384 Ref: Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. PMID: 19698189 Ref: Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. PMID: 19737956 Ref: Molecular targeting for treatment of advanced hepatocellular carcinoma. PMID: 19783879 Ref: Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. PMID: 20616913 Ref: Sorafenib for the treatment of hepatocellular carcinoma across geographic regions. PMID: 24410643 |
Ref: Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat. PMID: 19499222 Ref: Medical treatments: in association or alone, their roles and their future perspectives: the Western experience. PMID: 19890601 Ref: AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). PMID: 19910069 Ref: Sorafenib. PMID: 20072831 Ref: Targeted therapy of hepatocellular cancer. PMID: 20074016 Ref: Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/I PMID: 20149262 Ref: Hepatitis B virus X protein upregulates HSP90alpha expression via activation of c-Myc in human hepatocarcinoma cell line, HepG2. PMID: 20170530 Ref: Molecular genetics of hepatocellular neoplasia. PMID: 20182587 Ref: Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma. PMID: 20345479 Ref: Molecularly targeted therapy in hepatocellular carcinoma. PMID: 20371362 Ref: Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma. PMID: 20396977 Ref: Sorafenib: a clinical and pharmacologic review. PMID: 20586710 Ref: Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. PMID: 20616593 Ref: Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. PMID: 20616599 Ref: The role of signaling pathways in the development and treatment of hepatocellular carcinoma. PMID: 20639898 Ref: Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China. PMID: 20698202 Ref: Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. PMID: 20860815 Ref: PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. PMID: 21187475 Ref: Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. PMID: 21351273 Ref: Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. PMID: 24367212 |
Ref: Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. PMID: 20443129 Ref: Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. PMID: 20856226 Ref: Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer. PMID: 21216289 Ref: [Sorafenib and radiotherapy association for hepatocellular carcinoma]. PMID: 21239203 Ref: Effect of sorafenib on murine liver regeneration. PMID: 21274878 Ref: Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. PMID: 21316602 Ref: Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. PMID: 21324414 Ref: [Squamous cell carcinoma in a patient receiving sorafenib]. PMID: 21333823 Ref: Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. PMID: 21427706 Ref: Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. PMID: 21487053 Ref: Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies. PMID: 21599629 Ref: Growth differentiation factor 15 is induced by hepatitis C virus infection and regulates hepatocellular carcinoma-related genes. PMID: 21625435 Ref: A high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafish. PMID: 21729876 Ref: c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. PMID: 21734462 Ref: A DeltaRaf1-ER-inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures. PMID: 21744342 Ref: Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction. PMID: 21790999 Ref: Molecular targeted therapy for hepatocellular carcinoma: bench to bedside. PMID: 21829017 Ref: Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways. PMID: 22147992 Ref: Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. PMID: 22179180 |
Ref: Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. PMID: 21858812 Ref: An inducible kras(V12) transgenic zebrafish model for liver tumorigenesis and chemical drug screening. PMID: 21903676 Ref: Transforming growth factor-beta-stimulated clone-22 is a negative-feedback regulator of Ras / Raf signaling: Implications for tumorigenesis. PMID: 21943131 Ref: Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway. PMID: 22114332 Ref: Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. PMID: 22214462 Ref: PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. PMID: 22261591 Ref: Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). PMID: 22323095 Ref: Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. PMID: 22357220 Ref: Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclins A and E. PMID: 22406477 Ref: Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway. PMID: 22425622 Ref: Sorafenib for treatment of hepatocellular carcinoma: a systematic review. PMID: 22451120 Ref: Sorafenib in liver cancer. PMID: 22519770 Ref: Rational drug design for identifying novel multi-target inhibitors for hepatocellular carcinoma. PMID: 22583422 Ref: Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. PMID: 22596232 Ref: The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. PMID: 22753710 Ref: Analysis of possible mechanisms accounting for raf-1 kinase inhibitor protein downregulation in hepatocellular carcinoma. PMID: 23095110 Ref: Pathways and targets in hepatocellular carcinoma. PMID: 23176622 Ref: PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib. PMID: 23193917 Ref: Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. PMID: 23231599 Ref: IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal. PMID: 23341802 |
Ref: Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. PMID: 22777740 Ref: RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver. PMID: 22927239 Ref: Targeting tyrosine kinase receptors in hepatocellular carcinoma. PMID: 23016985 Ref: Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. PMID: 23145926 Ref: Claudin-1 as a promoter of EMT in hepatocellular carcinoma. PMID: 23318416 Ref: Recent topics on alpha-fetoprotein. PMID: 23347387 Ref: Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk. PMID: 23478801 Ref: Comparative mitochondrial proteomic analysis of hepatocellular carcinoma from patients. PMID: 23589362 Ref: Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. PMID: 23700287 Ref: Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells. PMID: 23721490 Ref: Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. PMID: 23726028 Ref: Wentilactone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK signaling pathway in human hepatoma SMMC-7721 cells. PMID: 23744357 Ref: PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. PMID: 23769634 Ref: Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. PMID: 23895220 Ref: Construction of a recombinant eukaryotic human ZHX1 gene expression plasmid and the role of ZHX1 in hepatocellular carcinoma. PMID: 24064680 Ref: [Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism]. PMID: 24331695 Ref: BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. PMID: 24391798 Ref: Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology. PMID: 24460304 Ref: Targeted therapies in development for non-small cell lung cancer. PMID: 24574860 Ref: The fibroblast growth factor receptor 2-mediated extracellular signal-regulated kinase 1/2 signaling pathway plays is important in regulating excision repair cross-complementary gene 1 expression in hepatocellular carcinoma. PMID: 24648994 Ref: Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines. PMID: 24649118 |
Ref: Targeted therapies in hepatocellular carcinoma. PMID: 23992323 Ref: Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. PMID: 24170769 Ref: Multi-kinase inhibition in ovarian cancer. PMID: 24309512 Ref: Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS. PMID: 24378831 Ref: Clinical significance of RKIP mRNA expression in non-small cell lung cancer. PMID: 24420151 Ref: Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. PMID: 24507059 Ref: Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. PMID: 24572810 Ref: Molecular therapies in hepatocellular carcinoma: what can we target? PMID: 24573715 Ref: Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option. PMID: 24692678 Ref: Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/beta-catenin pathways. PMID: 24692700 Ref: Sorafenib: targeting multiple tyrosine kinases in cancer. PMID: 24756790 Ref: Regorafenib. PMID: 24756792 Ref: beta-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma. PMID: 24848510 Ref: Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma. PMID: 24912819 Ref: Eupolyphaga sinensis walker displays inhibition on hepatocellular carcinoma through regulating cell growth and metastasis signaling. PMID: 24980220 Ref: Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts. PMID: 25051375 Ref: Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma. PMID: 25120700 Ref: Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma. PMID: 25195714 Ref: [Anti-tumor activity and mechanism of T03 in vitro and in vivo]. PMID: 25212033 Ref: Fatty acid esters of phloridzin induce apoptosis of human liver cancer cells through altered gene expression. PMID: 25229655 Ref: Integration of genomic information in the clinical management of HCC. PMID: 25260311 Ref: Identification of PAQR3 as a new candidate tumor suppressor in hepatocellular carcinoma. PMID: 25310770 Ref: Molecular profiling of liver tumors: classification and clinical translation for decision making. PMID: 25369299 Ref: Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma. PMID: 25376291 Ref: [Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism]. PMID: 26027111 Ref: Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors. PMID: 26158148 Ref: Overview of fundamental study of pazopanib in cancer. PMID: 26767042 Ref: Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives. PMID: 27508178 |
Ref: ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA. PMID: 25473899 Ref: MAPK signaling triggers transcriptional induction of cFOS during amino acid limitation of HepG2 cells. PMID: 25523140 Ref: Application of immunohistochemistry in gastrointestinal and liver neoplasms: new markers and evolving practice. PMID: 25549141 Ref: Rac1 promotes diethylnitrosamine (DEN)-induced formation of liver tumors. PMID: 25556150 Ref: Oncogenic KRAS promotes malignant brain tumors in zebrafish. PMID: 25644510 Ref: Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-kappaB signaling pathway in H22 tumor-bearing mice. PMID: 25720342 Ref: Methionine adenosyltransferase 2B-GIT1 complex serves as a scaffold to regulate Ras/Raf/MEK1/2 activity in human liver and colon cancer cells. PMID: 25794709 Ref: The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro. PMID: 25823619 Ref: The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. PMID: 25832714 Ref: Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression. PMID: 25862849 Ref: PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients. PMID: 25865556 Ref: psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling. PMID: 25890498 Ref: Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma. PMID: 25895026 Ref: Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence. PMID: 26059188 Ref: Caveolin-1 Confers Resistance of Hepatoma Cells to Anoikis by Activating IGF-1 Pathway. PMID: 26138883 Ref: Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. PMID: 26172295 Ref: TMPRSS4 facilitates epithelial-mesenchymal transition of hepatocellular carcinoma and is a predictive marker for poor prognosis of patients after curative resection. PMID: 26190376 Ref: A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation. PMID: 26237499 Ref: Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. PMID: 26257239 Ref: Taspine derivative TAS9 regulates cell growth and metastasis of human hepatocellular carcinoma. PMID: 26459497 Ref: Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma. PMID: 26488287 Ref: Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma. PMID: 26535060 Ref: Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. PMID: 26576091 Ref: Raf/ERK/Nrf2 signaling pathway and MMP-7 expression involvement in the trigonelline-mediated inhibition of hepatocarcinoma cell migration. PMID: 26699938 Ref: Sorafenib-induced Scrotal Eczema. PMID: 26839524 |
Ref: Aspafilioside B induces G2/M cell cycle arrest and apoptosis by up-regulating H-Ras and N-Ras via ERK and p38 MAPK signaling pathways in human hepatoma HepG2 cells. PMID: 25683703 Ref: TERT promoter mutations in primary liver tumors. PMID: 26336998 Ref: Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. PMID: 26364606 Ref: Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection. PMID: 26620707 Ref: MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. PMID: 26655273 Ref: A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells. PMID: 26794644 Ref: Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. PMID: 26943571 Ref: Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. PMID: 26981887 Ref: The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. PMID: 27102149 Ref: Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. PMID: 27167344 Ref: Two-Step Forward Genetic Screen in Mice Identifies Ral GTPase-Activating Proteins as Suppressors of Hepatocellular Carcinoma. PMID: 27178121 Ref: Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology. PMID: 27372199 Ref: Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. PMID: 27496136 Ref: Immunobiology of hepatocarcinogenesis: Ways to go or almost there? PMID: 27574562 Ref: Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways. PMID: 27654866 Ref: delta and gamma tocotrienols suppress human hepatocellular carcinoma cell proliferation via regulation of Ras-Raf-MEK-ERK pathway-associated upstream signaling. PMID: 27713963 Ref: The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. PMID: 27899961 Ref: A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis. PMID: 28000790 Ref: Antitumoral Activity of Sorafenib in Hepatocellular Carcinoma: Effects on Cell Survival and Death Pathways, Cell Metabolism Reprogramming, and Nitrosative and Oxidative Stress. PMID: 29431086 |
Ref: Promising new strategies for hepatocellular carcinoma. PMID: 27558453 Ref: Targeting Signalling Pathways in Hepatocellular Carcinoma. PMID: 27719638 Ref: Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients. PMID: 27936391 Ref: Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells. PMID: 28161506 Ref: Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function. PMID: 28179093 Ref: Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib. PMID: 28260092 Ref: Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway. PMID: 28276313 Ref: Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. PMID: 28276530 Ref: Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling. PMID: 28284560 Ref: SHP2 is induced by the HBx-NF-kappaB pathway and contributes to fibrosis during human early hepatocellular carcinoma development. PMID: 28460481 Ref: Flot2 promotes tumor growth and metastasis through modulating cell cycle and inducing epithelial-mesenchymal transition of hepatocellular carcinoma. PMID: 28560058 Ref: Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells. PMID: 28560380 Ref: Hepatitis B virus X protein promotes CREB-mediated activation of miR-3188 and Notch signaling in hepatocellular carcinoma. PMID: 28574502 Ref: Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma. PMID: 28577975 Ref: Modulation of Wnt signaling pathway by hepatitis B virus. PMID: 28685286 Ref: Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells. PMID: 28693200 Ref: MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma. PMID: 28732393 Ref: Cell-specific mechanisms of TMEM16A Ca(2+)-activated chloride channel in cancer. PMID: 28893247 Ref: Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma. PMID: 29030911 Ref: Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma. PMID: 29291014 |
Ref: Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway. PMID: 29156516 Ref: Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. PMID: 29251327 Ref: Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance. PMID: 29275358 Ref: Demethylation-Induced Overexpression of Shc3 Drives c-Raf-Independent Activation of MEK/ERK in HCC. PMID: 29330146 Ref: Clinical implications of the Hippo-YAP pathway in multiple cancer contexts. PMID: 29366445 Ref: Epigenetic basis of hepatocellular carcinoma: A network-based integrative meta-analysis. PMID: 29399289 Ref: Monocytes/Macrophages promote vascular CXCR4 expression via the ERK pathway in hepatocellular carcinoma. PMID: 29399411 Ref: miR-429 suppresses tumor migration and invasion by targeting CRKL in hepatocellular carcinoma via inhibiting Raf/MEK/ERK pathway and epithelial-mesenchymal transition. PMID: 29403024 Ref: Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option. PMID: 29423069 Ref: EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy. PMID: 29449645 Ref: Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. PMID: 29463989 Ref: Anticancer effects of a novel PanRAF inhibitor in a hepatocellular carcinoma cell line. PMID: 29484394 Ref: Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus. PMID: 29524828 Ref: Sp1-regulated transcription of RasGRP1 promotes hepatocellular carcinoma (HCC) proliferation. PMID: 29655291 Ref: The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target. PMID: 29706627 Ref: HCC Specific Protein Network Involving Interactions of EGFR with A-Raf and Transthyretin: Experimental Analysis and Computational Biology Correlates. PMID: 29732980 Ref: HBV suppresses ZHX2 expression to promote proliferation of HCC through miR-155 activation. PMID: 29752719 Ref: Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. PMID: 29806062 Ref: Pyran-2-one derivatives from Croton crassifolius as potent apoptosis inducers in HepG2 cells via p53-mediated Ras/Raf/ERK pathway. PMID: 29852310 Ref: Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines. PMID: 29858683 Ref: Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. PMID: 29881824 Ref: Regorafenib. PMID: 30069758 Ref: MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway. PMID: 30108016 Ref: Mouse hepatomas with Ha-ras and B-raf mutations differ in mitogen-activated protein kinase signaling and response to constitutive androstane receptor activation. PMID: 30115646 Ref: The role of Zhx2 transcription factor in bipolar cell differentiation during mouse retinal development. PMID: 30146259 Ref: Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma. PMID: 30292831 Ref: [Mechanism of angiotensin II (Ang II) on the proliferation of human hepatoma cell line HepG2 cells]. PMID: 30317792 Ref: Elevated expression of A-Raf and FA2H in hepatocellular carcinoma is associated with lipid metabolism dysregulation and cancer progression. PMID: 30324893 Ref: PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation. PMID: 30332648 Ref: Interplay of Wnt beta-catenin pathway and miRNAs in HBV pathogenesis leading to HCC. PMID: 30377095 |